Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28406604 | 0.83 | HDAC6 (0.57) | SMN1; SMN2NPC1RAB9AHDAC6KCNN3 | |
| SCHEMBL27898220 | 0.81 | RIPK1 (0.62) | SMN1; SMN2NPC1RAB9ALMNAHDAC6 | |
| SCHEMBL14155576 | 0.79 | RIPK1 (0.65) | SMN1; SMN2NPC1RAB9ALMNAHDAC6 | |
| SCHEMBL21432292 | 0.79 | HDAC6 (0.50) | SMN1; SMN2NPC1RAB9ALMNAHDAC6 | |
| SCHEMBL29502646 | 0.79 | HDAC6 (0.50) | SMN1; SMN2NPC1RAB9ALMNAHDAC6 | |
| SCHEMBL3546237 | 0.79 | KCNN3 (0.57) | SMN1; SMN2NPC1RAB9ALMNAHDAC6 | |
| SCHEMBL382481 | 0.78 | JAK1 (0.54) | SMN1; SMN2NPC1RAB9AHDAC6KCNN3 | |
| SCHEMBL8805952 | 0.78 | HDAC6 (0.51) | SMN1; SMN2NPC1RAB9ALMNAHDAC6 | |
| Hydrochloric Acid SCHEMBL5007369 | 0.77 | JAK1 (0.53) | SMN1; SMN2NPC1RAB9AHDAC6KCNN3 | |
| Hydrochloric Acid SCHEMBL8130344 | 0.77 | JAK1 (0.53) | SMN1; SMN2NPC1RAB9AHDAC6KCNN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | AMGEN INC. | 2016-09-29 | — | — | US | disclosed |
| US-8952037-B2 | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8952037-B2 | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors | AMGEN INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | INC., AMGEN | 2011-12-15 | — | — | US | disclosed |
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | INC., AMGEN | 2011-12-15 | — | — | US | disclosed |
| WO-2011143366-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | AMGEN INC. (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306591-A1 | HETEROARYLOXYCARBOCYCLYL COMPOUNDS AS PDE10 INHIBITORS | PDE10A, PDE9A, HDAC10 | SMN1; SMN2 3659/4885NPC1 1891/4885RAB9A 217/4885 |
| US-20160280703-A1 | Heteroaryloxycarbocyclyl Compounds as PDE 10 Inhibitors | PDE10A, PDE9A, PDE7A | SMN1; SMN2 3817/4885NPC1 2206/4885RAB9A 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.